Navigation Links
Landauer, Inc. Reports Fiscal 2012 Fourth Quarter And Year End Results
Date:12/10/2012

the prior year period, by currency fluctuation, principally due to weakness in the Euro and the Real against the U.S. dollar. 

Corporate expenses for shared functions, as well as acquisition and reorganization costs are recognized in the Radiation Measurement segment where they have been reported historically. As the Company's business model evolves, management may determine it necessary to change this reporting practice to reflect any appropriate allocations.

Radiation Measurement operating income, adjusted for the impact of acquisition related transaction expenses, asset abandonment charges, IT platform enhancement expenses, and non-cash stock based compensation expenses, for fiscal 2012 decreased 16.2 percent, or $6.4 million, to $33.1 million compared with adjusted operating income of $39.5 million for the comparable period in fiscal 2011.

Medical Physics SegmentMedical Physics revenues for fiscal 2012 of $30.9 million increased 50.3 percent, or $10.3 million, from the comparable period in fiscal 2011 of $20.6 million on $2.2 million of organic growth and $8.1 million due to the impact of acquired companies. The Medical Physics segment operating income of $2.1 million, or 6.7 percent of revenues (before trade name impairment charges $0.75 million, reorganization charges $0.32 million, and acquisition related charges $0.9 million), increased $1.6 million as compared to a loss of $0.5 million, for fiscal 2011. The improvement in operating income was primarily due to operating efficiencies in the core Medical Physics business and higher episodic premium services leveraging a relatively fixed cost structure, as well as higher volume sales inclusive of acquired companies.

Medical Products SegmentWith the acquisition of IZI on November 14, 2011, the Company now operates in a third reportable segment, Medical Products. Revenues for the period from the date of acquisition through September 30, 2012 were $13.5 million. Me
'/>"/>

SOURCE Landauer, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Landauer, Inc. Reports Fiscal 2012 Second Quarter Results
2. Landauer, Inc. Appoints Peter Cempellin To President Of Landauer Radiation Measurement
3. Landauer, Inc. Appoints Ronald Zilkowski To Vice President, Corporate Controller And Chief Accounting Officer
4. Landauer, Inc. Sets Date And Time For Announcement Of Fiscal Fourth Quarter And Full Year 2012 Results
5. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
6. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
7. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
8. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
9. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
11. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
(Date:4/23/2014)... A novel compound that targets an important brain ... cocaine addiction behaviors, including relapse behavior, a University at ... strong evidence that this may be a novel lead ... medications exist., The UB research was published as an ... , In the study, the compound, RO5263397, severely blunted ...
(Date:4/23/2014)... MD (April 23, 2014) The American Gastroenterological ... the 2014 AGA Research Scholars. The AGA Research ... investigators to develop independent and productive research careers ... Scholar Awards fund an additional year allowing for ... committed to supporting junior faculty who are paving ...
(Date:4/23/2014)... scientists led by a researcher from the Cancer Science ... of Singapore has identified the cancer specific stem cell ... possibility of developing new drugs for the treatment of ... research group, led by Dr Chan Shing Leng, Research ... time that a cancer-specific variant of a cell surface ...
(Date:4/23/2014)... have shown that proliferation of endogenous neural precursor ... neurons and axons. From the perspective of neural ... Yat-sen University in China observed the effects of ... cell proliferation and expression of basic fibroblast growth ... brain on the infarct side. The researchers found ...
(Date:4/22/2014)... few decades researchers have characterized a set of clock ... in all types of species, from flies to humans. ... researchers surmise there are more. A team from the ... wondered if big-data approaches could find them. , ... Hogenesch, PhD, professor of Pharmacology and first author Ron ...
Breaking Medicine News(10 mins):Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:AGA announces 2014 Class of AGA Research Scholars 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Bioinformatics profiling identifies a new mammalian clock gene 2
... March 18 German medical device,manufacturer Ziehm Imaging ... European Congress of Radiology (ECR) in Vienna. This ... requiring minimal OR space. The,system provides flexible image ... OR monitors. Ziehm Solo was designed to meet ...
... provider of comprehensive medical record solutions for healthcare ... on Wednesday, March 25th at their headquarters in ... Future" will focus on the rollout of the ... meant to promote the integration of electronic medical ...
... 17 The Generic Pharmaceutical Association (GPhA) released the ... Jaeger regarding the introduction of H.R. 1548, "The Pathway ... is the wrong road for patients looking for safe ... times. It is a long route filled with ...
... Teva Pharmaceuticals USA, the leading generic pharmaceutical company, ... Senior Vice President of Government Affairs on the ... Eshoo and Joe Barton: "In this year of ... to affordable medicines. The legislation re-introduced in the ...
... University of Illinois at Chicago College of Medicine have ... protein snarls found in the brains of Alzheimer,s patients ... needed to combat the neurodegenerative disease. , Alzheimer,s disease, ... and is among the most costly diseases to society ...
... WASHINGTON, March 17 A federal jury in Miami ... connection with a $5.3 million Medicare fraud scheme, Acting ... Division and U.S. Attorney R. Alexander Acosta of the ... federal court in Miami, a jury found David Rothman, ...
Cached Medicine News:Health News:Ziehm Imaging Introduces Ziehm Solo C-arm, Featuring a Versatile set-up in the OR and Exceptional Image Quality 2Health News:Ziehm Imaging Introduces Ziehm Solo C-arm, Featuring a Versatile set-up in the OR and Exceptional Image Quality 3Health News:Microwize to Hold Free Stimulus Package Workshop for Medical Industry 2Health News:Microwize to Hold Free Stimulus Package Workshop for Medical Industry 3Health News:GPhA Statement on Introduction of H.R. 1548, 'The Pathway for Biosimilars Act' 2Health News:Mechanism of Alzheimer's suggests combination therapy needed 2Health News:Mechanism of Alzheimer's suggests combination therapy needed 3Health News:Jury Convicts Two Doctors and Two Medical Assistants in $5.3 Million Medicare Fraud Scam 2Health News:Jury Convicts Two Doctors and Two Medical Assistants in $5.3 Million Medicare Fraud Scam 3Health News:Jury Convicts Two Doctors and Two Medical Assistants in $5.3 Million Medicare Fraud Scam 4
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: